Best Life Sciences Companies in Missouri, United States
The 158 best Life Sciences companies in Missouri, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Arch Oncology.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Missouri
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Arch Oncology Developer of anti-CD47 antibodies for the treatment of solid tumors | $250M | 61 mo ago | 28 | 2006 | — | — | 73 patents CD47-targeted antibody therapeutics and combination immuno‑oncology formulations | — |
| 2 | Veran Medical Provider of diagnosis of lung cancer by soft tissue navigation | $155M | 90 mo ago | 126 | 2005 | — | WordPressMySQLPHP+24 | 195 patents Ultrasound‑guided minimally invasive catheters for ablation monitoring and pulmonary diagnostics | — |
| 3 | Wugen Developer of CAR-T cell therapy for treatingT-cell malignancies 64Talent top 15%Funding top 21%Patents top 26%Moat top 28% All 9 signals ▾Talenttop 15% Fundingtop 21% Patentstop 26% Moattop 28% Innovationtop 30% Techbottom 45% Marketbottom 43% Globalbottom 40% Newsbottom 22% Talent: Analyst team rating 5/5 Funding: Raised $136M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $136M | 9 mo ago | 81 | 2018 | — | WordPressMySQLPHP+24 | 41 patents Immunotherapy platforms: memory NK cell expansion, CD3‑engineered immune cells, CARs, bispecific antibodies | 1 job opening |
| 4 | Geneoscopy Developer of non-invasive biomarker tests for colorectal cancer | $114M | 17 mo ago | 61 | 2015 | — | WordPressApple iCloud MailGoogle Workspace+24 | 14 patents Non‑invasive stool‑based nucleic‑acid diagnostics for IBD and colorectal cancer detection | 1 internship · 1 launch · 2 partnerships |
| 5 | MediBeacon Innovating fluorescent technology for improved patient care and disease management | $86M | 33 mo ago | 25 | 2011 | Richard Dorshow Co-Founder & CSO | — | 333 patents Patents concentrated in health & consumer products | — |
| 6 | EndoStim Developing neurostimulation treatment for drug-refractory gastroesophageal reflux disease (GERD) | $76M | 89 mo ago | 4 | 2009 | Virender Sharma Founder | — | 128 patents Implantable electrical stimulation devices for gastrointestinal neuromodulation therapy | — |
| 7 | PierianDx Provider of genetic tests for individualized diagnosis of multiple diseases | $69M | 55 mo ago | 84 | 2014 | Rakesh Nagarajan Founder | HubSpot CMS HubBugHerdApple iCloud Mail+18 | — | — |
| 8 | Adarzabio Next-generation tools transforming medical research and diagnostic testing | $66M | 76 mo ago | 13 | 2008 | — | — | — | — |
| 9 | Veniti Stent system for chronic venous disease | $65M | 117 mo ago | 28 | 2010 | — | — | 55 patents Advanced vascular stent designs and delivery mechanisms for improved fracture resistance | — |
| 10 | Young Innovations Portfolio of dental equipment | $58M | 159 mo ago | 557 557 → 500 (-10%) | 1995 | — | — | — | 1 launch · 1 award |
| 11 | Stereotaxis Surgical robotics company advancing minimally invasive endovascular intervention for improved patient care | $52M | 72 mo ago | 122 122 → 193 (+58%) | 1990 | — | DrupalPHPSalesforce+29 | 257 patents Magnetically guided robotic catheters for cardiac electrophysiology and remote interventional navigation | 1 launch |
| 12 | CoverCress Developer of sustainable agriculture technology for farm profitability and promoting renewable energy | $48M | 49 mo ago | 37 | 2013 | — | WebflowApple iCloud MailMicrosoft 365+19 | 40 patents Processing low‑glucosinolate, low‑fiber pennycress meals for plant‑protein food ingredients | 1 launch · 1 partnership |
| 13 | Appistry Developer of tools for clinical labs, hospitals to practice genomically enhanced medicine | $44M | 124 mo ago | 16 | 2001 | Guerry Semones Co-Founder | — | 21 patents Distributed, fault‑tolerant middleware for request‑process‑task handling in networked computing | — |
| 14 | MC3 Cardiopulmonary Cardiopulmonary surgical instruments | $34M | 13 mo ago | 27 | 1991 | — | — | — | — |
| 15 | Cardialen Developer of cardioversion therapy for atrial fibrillation | $28M | 57 mo ago | 8 | 2008 | — | — | 10 patents Patents concentrated in health & consumer products | — |
| 16 | Immunophotonics Developer of therapeutics for the treatment of interventional immuno-oncology | $28M | 27 mo ago | 17 | 2008 | Robert Nordquist Co-Founder | WordPressPleskMySQL+20 | 63 patents Chitosan-derived glycated biopolymers for immune modulation and antiviral therapies | 1 launch |
| 17 | LPOXY Therapeutics Developer of therapies for infectious disease prevention 24Funding top 42%Talent bottom 49%Global bottom 25%News bottom 18% All 4 signals ▾Fundingtop 42% Talentbottom 49% Globalbottom 25% Newsbottom 18% Funding: Raised $28.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 24/100 | $28M | 9 mo ago | — | 2020 | Larry Sutton President & Founder | — | — | — |
| 18 | Kereos Provides biopharma developing nanotechnology therapeutics to target tumors | $27M | 176 mo ago | 2 | 1999 | Gregory M. Lanza Co-Founder and Chief Scientific Officer | — | 26 patents Targeted cancer therapeutics using novel linker chemistries for drug conjugates | — |
| 19 | InterShunt Technologies Developer of cardiac catheter for the treatment of cardiac diseases | $27M | 22 mo ago | 7 | 2015 | Gil Vardi Founder | — | 2 patents Percutaneous creation of atrial septal openings for cardiac catheter interventions | — |
| 20 | Indalo Therapeutics Developing small molecules targeting RGD-binding integrins to treat fibrotic diseases | $26M | 106 mo ago | 8 | 2016 | Peter Ruminski Co-founder | — | — | — |
| 21 | DeepSight Developer of advanced ultrasound imaging technology for medical diagnostics and interventions | $25M | 56 mo ago | 28 | 2019 | Lan Yang Co-Founder & Chief Technology Officer | WordPressMySQLPHP+18 | — | — |
| 22 | C₂N Diagnostics Developer of diagnostics and therapies for Alzheimer's disease | $25M | 13 mo ago | 41 | 2007 | Ilana Fogelman Co-Founder | Cart FunctionalitySquarespace CommerceSquarespace+13 | 94 patents Patents concentrated in computing, sensing & instrumentation | — |
| 23 | ISTO Biologics Developer of treatments for cartilage and bone problems | $24M | 130 mo ago | 17 | 1997 | — | HubSpot CMS HubSalesforceHubSpot+18 | — | — |
| 24 | Plastomics Developer of next-generation trait delivery technology for higher-yielding crops and sustainable agriculture 29Funding top 32%Moat top 37%News top 44%Patents top 46% All 8 signals ▾Fundingtop 32% Moattop 37% Newstop 44% Patentstop 46% Innovationtop 50% Talentbottom 49% Marketbottom 33% Globalbottom 33% Funding: Raised $12.7M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 6 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $13M | 7 mo ago | 23 | 2016 | Jeffrey Staub Founder and Chief Scientist | — | 6 patents Plastid genetic engineering for plant trait modification and gene silencing | — |
| 25 | Chlorogen Developer of vaccines for the treatment and prevention of human diseases | $12M | 245 mo ago | — | 2001 | Henry Daniell Founder | — | 2 patents Engineering plant plastids to produce therapeutic TGF-β proteins | — |
| 26 | Divergence Genomics and informatics for control of parasites | $12M | 206 mo ago | 26 | 1999 | — | — | 160 patents Patents concentrated in computing, sensing & instrumentation | — |
| 27 | Mobius Therapeutics Ophthalmic surgery solutions | $11M | 151 mo ago | 9 | 2006 | — | — | — | — |
| 28 | Elira Developer of wearable device for controlling appetite | $11M | 41 mo ago | 12 | 2004 | Danika Harrison CEO & President | — | 41 patents Transcutaneous electrical stimulation devices for glucose‑guided weight loss and appetite control | — |
| 29 | Radiologics Clinical trial software for imaging | $11M | 13 mo ago | 2 | 2008 | Daniel Marcus Founder & President | — | — | — |
| 30 | Fimbrion Therapeutics Pioneering anti-virulence therapeutics for urinary tract infections and tuberculosis | $10M | 10 mo ago | 6 | 2012 | James Janetka Co-Founder | — | — | — |
| 31 | Endevica Bio Developer of therapeutic drugs for the treatment of cancer cachexia | $10M | 41 mo ago | 5 | 2009 | Kenneth Gruber Founder & Chief Scientific Officer | WordPress Block EditorWordPressApple iCloud Mail+18 | — | 1 job opening |
| 32 | Eternogen Creative assets, tools, and tutorials empowering creative professionals to thrive | $9M | 127 mo ago | 6 | 2009 | — | — | — | — |
| 33 | BacterioScan Bacterial screening device for diagnosis and treatment of infectious diseases | $8M | 101 mo ago | 14 | 2004 | Dana Marshall Chief Executive Officer and President | — | 14 patents Rapid optical detection and antibiotic susceptibility testing of microbes in fluid samples | — |
| 34 | Kultevat Developer of biomaterials using dandelion as a sustainable resource | $6M | 13 mo ago | 3 | 2008 | Dan Swiger Founder & CEO | — | 47 patents Continuous stirred-tank solvent extraction technology for rubber and chemical by‑product recovery | — |
| 35 | Acera Surgical Provider of synthetic electrospun scaffolds for regenerative medical applications | $6M | 92 mo ago | 98 | 2013 | — | Apple iCloud MailMicrosoft 365Windows Server+12 | 55 patents Hybrid-scale fiber matrices for advanced tissue engineering and regenerative medical implants | 1 partnership |
| 36 | Senseion Therapeutics Developer of therapeutics for the treatment of metabolic diseases | $6M | 15 mo ago | — | 2019 | Rajan Sah Co-Founder | — | — | — |
| 37 | Keystone Bio Developer of biotherapeutics for the treatment of multiple diseases | $5M | 85 mo ago | 3 | 2017 | Garth Ehrlich Co-Founder | — | — | — |
| 38 | Mediomics Innovative assay kits and biosensors for research, diagnostics, and therapeutics | $5M | 71 mo ago | — | 2001 | Yie Hwa Chang Founder | — | 41 patents Multiplexed, signal‑amplified molecular biosensors for detecting specific biomolecular epitopes | — |
| 39 | Sparo App and smart spirometer for detecting lung health | $4M | 95 mo ago | 4 | 2012 | Abigail Cohen Co-Founder & Co-CEO | — | 18 patents Home-based spirometry devices with gamified data collection and automated analysis | — |
| 40 | Omniose Developer of polysaccharide conjugate vaccines against bacterial threats | $4M | 32 mo ago | 7 | 2016 | Christine Szymanski Co-Founder | — | — | — |
| 41 | RNAgri Biotechnology company developing RNA production technology | $3M | 98 mo ago | — | 2011 | Juan Arhancet Founder | — | — | — |
| 42 | NeuroLutions Developer of robotic glove controlled by brain | $2M | 16 mo ago | 9 | 2007 | Eric Leuthardt Co-Founder | WordPressApple iCloud MailGoogle Workspace+27 | 70 patents BCI-driven neurorehabilitation and assistive orthotic devices for motor control and pain relief | — |
| 43 | APT Therapeutics Transforming human apyrase into life-saving medicine for thrombotic diseases | $2M | 14 mo ago | 2 | 2001 | — | — | — | — |
| 44 | Kinimmune Developer of immuno-therapeutics for solid tumors | $1M | 17 mo ago | — | 2020 | Cory Berkland Co-Founder & CEO | — | — | — |
| 45 | KaloCyte Developer of a nanotechnology-based red blood cell substitute | $1M | 12 mo ago | 8 | 2016 | Dipanjan Pan Co-Founder | WordPressApple iCloud MailZoho+23 | 28 patents Lipid nanoparticle oxygen carriers for hemorrhagic shock and bio‑synthetic nanoparticle clearance | — |
| 46 | Oncoblaze Developer of technology for precision delivery of chemotherapy after surgery | $649K | 21 mo ago | — | 2023 | Dieter Haemmerich CEO | — | 2 patents Targeted peptide-based drug delivery systems for surgical margin treatment | 1 launch |
| 47 | DOJO LABS Developer of supplements for cognitive health | $500K | 39 mo ago | 4 | 2021 | Brian Goldberg Co-Founder | — | — | — |
| 48 | Buck Surgical Developer of medical devices for anastomotic procedures | $350K | 14 mo ago | — | 2021 | Donald Buck Ii Md Facs Founder | — | — | — |
| 49 | Cicadea Biotech Developer of PCR-based assays | $305K | 14 mo ago | — | 2018 | Lucy Burns Founder & CEO | — | — | — |
| 50 | Far UV Technologies Developer of UV-light based device for surface and air disinfection | $100K | 18 mo ago | 9 | 2016 | P Piper Founder & CEO | Cart FunctionalityWooCommerceWordPress+36 | — | 2 launchs |
Top 12 Life Sciences companies in Missouri
#1
Series C · St. Louis, Missouri · founded 2018 · 81 employees$135.7Mraised▾
Developer of CAR-T cell therapy for treating T-cell malignancies. The company has developed an allogeneic CAR-T therapy platform for the treatment. Deletion of the T-cell receptor (TCR) enables the use of T-cells from healthy donors without the risk of life-threatening Graft vs. Host Disease (GvHD). It has developed a pipeline for Head & Neck Cancer, Melanoma, and Solid Tumors.
- Aug 2025Series C$115M
- Jul 2021Series B$98.5M
- Apr 2020Series A$37.2M
- 2019Seed—
#2
Series B · St. Louis, Missouri · founded 2016 · 23 employees$12.7Mraised▾
Developer of next-generation trait delivery technology for higher-yielding crops and sustainable agriculture. It offers a platform that places beneficial traits in the chloroplast of plant cells, enhancing crop performance. This approach simplifies product development, improves product effectiveness, and creates new market opportunities. The technology enables crops to better withstand insects, diseases, and weeds, leading to higher yields. By focusing on chloroplast trait introduction, they address challenges like pest resistance, trait outcrossing, and complex trait integration. This platform offers solutions for seed companies, providing a valuable tool to help growers meet the nutritional needs of a growing population. The technology supports sustainable agriculture by reducing the need for chemicals and enhancing crop resilience.
- Oct 2025Series B$5.8M
- Nov 2021Series A$7.1M
- May 2021Series A$3.2M
- Mar 2021Series A$2.4M
#3
Series A · Platte City, Missouri · founded 2020$28Mraised▾
Developer of therapies for infectious disease prevention. It offers an oral therapeutic, Sidiprev, which aims to prevent Clostridioides difficile infection by delivering oxygen directly to the bowel.
- Sep 2025Series A$28M
#4
Series C · St. Louis, Missouri · founded 2015 · 61 employees$113.9Mraised▾
Developer of non-invasive biomarker tests for colorectal cancer. The flagship assay analyzes stool samples for a panel of disease-associated mRNA biomarkers using a proprietary diagnostic algorithm to detect colorectal cancer. The company plans that its assay will be used to screen patients in need of a more invasive colonoscopy.
- Jan 2025Series C$105M
- Nov 2021Series B$105M
- Nov 2021Conventional Debt—
- Sep 2019Series A$7.9M
#5
Series C · Dexter, Missouri · founded 1991 · 27 employees$34Mraised▾
MC3 Cardiopulmonary, a spin-off of the University of Michigan, targets the Cardiopulmonary markets, having an intellectual property related to artificial heart and lung technologies. The company's devices are used for cardiac and pulmonary function support during surgery and for chronic support. In Nov 2015, the company acquired cardiac surgery cannula product lines from Terumo Cardiovascular Systems, which includes brand names such as the Sarns Soft-Flow arterial cannula.
- May 2025Grant (prize money)$1.1M
- Nov 2015Series C$34M
- Sep 2009Grant (prize money)$794.1K
- Apr 2009Grant (prize money)$3.7M
#6
Series B · St. Louis, Missouri · founded 2007 · 41 employees$25Mraised▾
Developer of diagnostics and therapies for Alzheimer's disease. The product include PrecivityAD blood test that is intended for use in patients with cognitive impairment and to determine the presence or absence of amyloid plaques in the brain. It also offers bioanalytical services for pharmaceutical and biotechnology companies.
- May 2025Conventional Debt$10M
- Mar 2025Series B$10M
- Oct 2024Grant (prize money)$15M
- Sep 2024Grant (prize money)$7M
#7
Funding Raised · St. Louis, Missouri · founded 2012 · 6 employees$10.3Mraised▾
Pioneering anti-virulence therapeutics for urinary tract infections and tuberculosis. The company focuses on developing novel antibacterial therapies and alternatives to traditional antibiotics. They are dedicated to creating powerful solutions to combat infectious diseases, particularly urinary tract infections and tuberculosis. Their pipeline includes oral antibacterial co-development and antibiotic-sparing approaches. They are committed to pioneering anti-virulence solutions, researching and developing innovative treatments. The company's work has potential social impact by addressing antibiotic resistance. They are involved in drug discovery and development, aiming to provide effective treatments for infectious diseases.
- Jul 2025Grant (prize money)$300K
- May 2025Grant (prize money)$600K
- Feb 2025Grant (prize money)$3M
- Mar 2023Grant (prize money)$600K
#8
Acquired · Saint Louis, Missouri · founded 2008 · 2 employees$10.5Mraised▾
Radiologics provides clinical trial software for imaging. XNAT CR, their platform helps in image data management for clinical trials. The platform offers file transfer and verification, integration with clinical data, automation of image processing routines, and connectivity with preferred imaging workstations. It has DICOM features that enable secure storage, verification, query, and retrieval of DICOM data.
- May 2025Grant (prize money)$8.7M
- Sep 2020Grant (prize money)$255.9K
- Sep 2017Grant (prize money)$1.5M
- 2016Grant (prize money)$50K
#9
Series A · Creve Coeur, Missouri · founded 2008 · 3 employees$6.3Mraised▾
Developer of biomaterials using dandelion as a sustainable resource. The company focuses on replacing petrochemical polymers with dandelion biomaterials. It promotes regenerative agriculture practices and aims to eliminate emissions from daily products. The company offers natural rubber, resin, inulin, and fiber.
- May 2025Grant (prize money)$600K
- Sep 2023Grant (prize money)$600K
- Apr 2021Grant (prize money)$100.1K
- Apr 2020Series A$4.8M
#10
Funding Raised · St. Louis, Missouri · founded 2019$6.3Mraised▾
Developer of therapeutics for the treatment of metabolic diseases. The company uses in vivo genetic models reveal SWELL1/LRRC8 Channels to regulate essential metabolic and cardiovascular function. The company product include SN-40X for the treatment of diabetes and its complications, including cardiovascular disease.
- Mar 2025Grant (prize money)$2.3M
- Sep 2023Grant (prize money)$1.3M
- Sep 2021Grant (prize money)$990.9K
- Sep 2020Grant (prize money)$1.4M
#11
Series B · Louisiana, Missouri · founded 2015 · 7 employees$26.6Mraised▾
InterShunt Technologies is a developer of the cardiac catheter for the treatment of cardiac diseases. The company has developed the intershunt atrial septostomy catheters that allow precise capture, cut, and excision of tissue from the interatrial septum which helps in reducing the elevated left atrial pressure.
- Aug 2024Series B$23.4M
- Jan 2021Series A$3.1M
- Jul 2018Seed—
#12
Seed · St. Louis, Missouri · founded 2016 · 8 employees$1.1Mraised▾
Developer of a nanotechnology-based red blood cell substitute. It offers ErythroMer an immuno-silent nanoparticle that emulates the surface of an RBC and allows for physiologically relevant gas exchange due to the presence of an embedded molecular shuttle that exhibits context-dependent oxygen binding. The technology is targeted toward patient care in low-resource settings such as battlefields, remote locations, etc. to reduce mortality from trauma-related blood loss.
- May 2025Grant (prize money)$3M
- Feb 2025Grant (prize money)$500K
- Apr 2024Grant (prize money)$2.5M
- Jul 2022Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology in Missouri is moving
A read on the academic research around Biotechnology in Missouri — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 41 papers.
University of Missouri leads Missouri's biotechnology research, focusing on animal genetics, reproductive biology, and soybean genomics, with a cautiously optimistic tone amid recent surging output.
- University of Missouri30
- University of Missouri–St. Louis6
- Missouri College5
- University of Missouri–Kansas City4
- Missouri Breaks Industries Research1
- Gene3
- Genome2
- Mutation2
- Genomics2
- Ovulation1
- Gene3
- Myofibroblast2
- Trait2
- Resistance (ecology)2
- Embryo2
- Gene2
- Agriculture2
- Germplasm2
- Cultivar2
- Correlation1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.